7498 Results (Page 293 of 300)
Pharmaceuticals Markets Research Reports
US Clinical Nutrition for Chronic Kidney Diseases Market Analysis
US Clinical Nutrition for Chronic Kidney Diseases Market was valued at $659.40 Mn in 2023 and is predicted to grow at a CAGR of 4.03% from 2023 to 2030, to $869.50 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, growing awareness and diagnosis, advancements in medical research, and the aging population. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Saudi Arabia Brugada Syndrome Market Analysis
The Saudi Arabia Brugada Syndrome Market was valued at $20.4 Mn in 2023 and is predicted to grow at a CAGR of 9.3% from 2023 to 2030, to $38 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, aging population, and advancements in genetic testing. The prominent players of the Saudi Arabia Brugada Syndrome Market are Jamjoom Pharma, Baxter, Riyadh Pharma, Sanofi, Novartis, and AstraZeneca, among others.
Singapore Actinic Keratosis Therapeutic Market Analysis
The Singapore Actinic Keratosis Therapeutic Market is expected to grow at a CAGR of 5.5% during the forecast period, rising from $8 Mn in the year 2022 and reaching $13 Mn by the year 2030. Factors contributing to the Singapore Actinic Keratosis Therapeutic Market growth include rising healthcare expenditures, an aging population, changing weather patterns, and patient preferences for convenient and effective treatment modalities. Key players in the Singapore Actinic Keratosis Therapeutic Market include LEO Pharma, Galderma, Sun Pharmaceuticals, Bayer, Alma Lasers, Syneron Candela, Novartis and Bausch Health among others
France Brain Cancer Therapeutics Market
France Brain Cancer Therapeutics Market valued at $63 Mn in 2022, projected to reach $132 Mn by 2030 with a 9.6% CAGR. The anticipated increase in brain cancer cases, particularly glioblastoma multiforme, is expected to be a key factor propelling the demand for brain cancer therapeutics, shaping the overall market landscape. Prominent players in the pharmaceutical sector currently operating are Roche, Merck & Co., Bristol Myers Squibb, Novartis, Pfizer, AstraZeneca, Eli Lilly, Sanofi, Takeda Pharmaceutical, and AbbVie.
Saudi Arabia Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Saudi Arabia Clinical Nutrition for Chronic Kidney Diseases Market was valued at $26.70 Mn in 2023 and is predicted to grow at a CAGR of 7.53% from 2023 to 2030, to $44.40 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, technological advancements, and increasing healthcare expenditure. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
UAE Brugada Syndrome Market Analysis
The UAE Brugada Syndrome Market was valued at $6 Mn in 2023 and is predicted to grow at a CAGR of 8.8% from 2023 to 2030, to $10.8 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, aging population, and advancements in genetic testing. The prominent players of the UAE Brugada Syndrome Market are Julphar, Neopharma, Novartis, Boehringer Ingelheim, and Gulf Scientific Corporation, among others.
South Africa Actinic Keratosis Therapeutic Market Analysis
South Africa Actinic Keratosis Therapeutic Market is expected to expand at a CAGR of 6.13% from $44 Mn in 2022 to $71 Mn by 2030. The South Africa Actinic Keratosis Therapeutic Market is poised for continued growth, driven by rising awareness, technological advancements, and an expanding healthcare sector and addressing access and affordability challenges will be crucial to ensure optimal market growth. Global giants like Galderma, Meda Pharmaceuticals, Merck & Co, Bausch, GlaxoSmithCline, etx coexist with smaller regional firms like Aspen Pharmacare, Adcock Ingram, Biovac, Clinitec etc as major participants in the South Africa, which is constantly changing
Malaysia Brain Cancer Therapeutics Market
Malaysia Brain Cancer Therapeutics Market valued at $4 Mn in 2022, projected to reach $8 Mn by 2030 with a 10.8% CAGR. The expected rise in instances of brain cancer, specifically glioblastoma multiforme, is projected to significantly enhance the demand for therapies aimed at treating brain cancer, thereby influencing the overall structure of the market. Top leading pharmaceutical companies presently operating in the market are Merck & Co, Amgen, Roche, Pfizer, Teva Pharmaceutical, Karyopharm Therapeutics, Novartis, AstraZeneca, Bristol Myers Squibb, and Eli Lilly.
Singapore Constipation Therapeutics Market Analysis
Singapore Constipation Therapeutics Market was valued at $22 Mn in 2022 and is estimated to reach $38 Mn in 2030, exhibiting a CAGR of 7.1% during the forecast period. The global growth of the constipation therapeutics market is driven by factors such as aging, sedentary lifestyles, and unhealthy dietary habits. The increasing elderly population, susceptible to chronic conditions, notably contributes to this expansion. Major players in this sector comprise GlaxoSmithKline, Johnson & Johnson, Sanofi, Abbott, Bayer, AstraZeneca, Pfizer, Merck Sharp & Dohme, Boehringer Ingelheim, and United Laboratories.
UAE Clinical Nutrition for Chronic Kidney Diseases Market Analysis
UAE Clinical Nutrition for Chronic Kidney Diseases Market was valued at $7.80 Mn in 2023 and is predicted to grow at a CAGR of 7.03% from 2023 to 2030, to $12.60 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, growing awareness and diagnosis, advancements in medical research, and the aging population. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Brazil Brugada Syndrome Market Analysis
The Brazil Brugada Syndrome Market was valued at $30 Mn in 2023 and is predicted to grow at a CAGR of 8.8% from 2023 to 2030, to $54.1 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, increasing awareness and diagnosis, and advancements in genetic testing. The prominent players of the Brazil Brugada Syndrome Market are Eurofarma, EMS Pharma, Sanofi, Novo Nordisk, and Novartis, among others.
Mexico Brain Cancer Therapeutics Market
Mexico Brain Cancer Therapeutics Market valued at $35 Mn in 2022, projected to reach $79 Mn by 2030 with a 10.85% CAGR. The demand for brain cancer therapeutics is projected to be fuelled by the expected increase in the occurrence of brain cancer, particularly glioblastoma multiforme. This surge in demand for therapeutic interventions is likely to shape the market landscape. Notable participants in the pharmaceutical sector include Pfizer, AstraZeneca, Merck & Co., Siemens, Carestream Health, Eisai Co., Genentech, Bristol-Myers Squibb, Eli Lilly, and Sanofi.
South Africa Constipation Therapeutics Market Analysis
South Africa Constipation Therapeutics Market was valued at $118 Mn in 2022 and is estimated to reach $215 Mn in 2030, exhibiting a CAGR of 7.73% during the forecast period. The constipation therapeutics market is experiencing worldwide expansion due to factors like aging, sedentary lifestyles, and poor dietary habits. The growing elderly demographic, prone to chronic conditions, plays a significant role in driving this growth. Key players in this industry include AstraZeneca, Bayer AG, Sanofi, Sucampo Pharmaceuticals, Takeda Pharmaceutical, Synergy Pharmaceuticals, Ironwood Pharmaceuticals, Salix Pharmaceuticals, Abbott Laboratories and Cosmo Pharmaceuticals NV.
Brazil Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Brazil Clinical Nutrition for Chronic Kidney Diseases Market was valued at $39.20 Mn in 2023 and is predicted to grow at a CAGR of 7.03% from 2023 to 2030, to $63.10 Mn by 2030. The key drivers of this industry include the rising prevalence of CKD, technological advancements, and increasing healthcare expenditure. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Mexico Brugada Syndrome Market Analysis
The Mexico Brugada Syndrome Market was valued at $18 Mn in 2023 and is predicted to grow at a CAGR of 8.05% from 2023 to 2030, to $30.9 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, geriatric population, and advancements in genetic testing. The prominent players of the Mexico Brugada Syndrome Market are Bayer, Roche, Teva, Medtronic, Abbott Laboratories, and Sanofi, among others.
UK Actinic Keratosis Therapeutic Market Analysis
The UK Actinic Keratosis Therapeutic Market is predicted to develop at a CAGR of 2.9%, increasing from $177 Mn in the year 2022 to $222 Mn by the year 2030. The UK Actinic Keratosis Therapeutic Market is expected to grow at a faster rate during the forecast period, owing to a large patient population, increased awareness about the prevention and treatment of Actinic Keratosis, and advancements in medical technology leading to the development of innovative and minimally invasive procedures. Some domestic firms, such as GlaxoSmithKline and Scancell, as well as international Sun Pharmaceuticals, Biofrontera, Nestle, Bausch Health, etc are key competitors in the industry
Indonesia Brain Cancer Therapeutics Market
Indonesia Brain Cancer Therapeutics Market valued at $14 Mn in 2022, projected to reach $31 Mn by 2030 with a 10.6% CAGR. The anticipated increase in cases of brain cancer, particularly glioblastoma multiforme, is expected to markedly boost the need for brain cancer therapeutics, shaping the overall market landscape significantly. The top leading pharmaceutical companies currently operating in the market are Roche, Novartis, Pfizer, Merck, AstraZeneca, Bristol Myers Squibb, Eli Lilly, Sanofi, Johnson & Johnson and Takeda.
Spain Constipation Therapeutics Market Analysis
Spain Constipation Therapeutics Market was valued at $351 Mn in 2022 and is estimated to reach $539 Mn in 2030, exhibiting a CAGR of 5.5% during the forecast period. The constipation therapeutics market is experiencing growth driven by the rising prevalence of constipation worldwide, attributed to factors like aging, sedentary lifestyles, and unhealthy dietary habits, with the expanding elderly population, more prone to chronic conditions, further contributing to this market expansion. Notable participants in this industry include AbbVie, Almirall, Boehringer Ingelheim, Ferring Pharmaceuticals, Ipsen Pharma, Johnson & Johnson, Norgine Pharmaceuticals, Pierre Fabre Médicament, Recordati, and Sanofi.
Mexico Clinical Nutrition for Chronic Kidney Diseases Market Analysis
Mexico Clinical Nutrition for Chronic Kidney Diseases Market was valued at $23.60 Mn in 2023 and is predicted to grow at a CAGR of 6.28% from 2023 to 2030, to $36.1 Mn by 2030. The key drivers of this industry include rising CKD prevalence, increased awareness, and advancements in medical research. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
France Brugada Syndrome Market Analysis
The France Brugada Syndrome Market was valued at $33 Mn in 2023 and is predicted to grow at a CAGR of 6.8% from 2023 to 2030, to $52.3 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, increased awareness and diagnosis, and technological innovations in treatment. The prominent players of the France Brugada Syndrome Market are Abbott Laboratories, Medtronic, Siemens Healthcare, Sanofi, and Abivax, among others.
Vietnam Actinic Keratosis Therapeutic Market Analysis
The Vietnam Actinic Keratosis Therapeutic Market is expected to grow at a CAGR of 5.13% during the forecast period, rising from $34 Mn in the year 2022 and reaching $51 Mn by the year 2030. The Vietnam Actinic Keratosis Market is driven by factors like the introduction of new products, a focus on market penetration in developing regions, and the rising demand and acceptance of minimally invasive procedures. Key players in the Vietnam Actinic Keratosis Therapeutic Market include global market players like LEO Pharma, Galderma, Sun Pharmaceuticals, Bayer, Alma Lasers, Syneron Candela, and some domestic players like Vinpharmex and Traphaco
France Clinical Nutrition for Chronic Kidney Diseases Market Analysis
France Clinical Nutrition for Chronic Kidney Diseases Market was valued at $43.20 Mn in 2023 and is predicted to grow at a CAGR of 5.03% from 2023 to 2030, to $60.90 Mn by 2030. The key drivers of this industry include rising CKD prevalence, aging populations, and technology advancements. The industry is primarily dominated by Abbott Nutrition, Pfizer Inc., Bayer AG, and Nestlé Health Science among others.
Germany Brugada Syndrome Market Analysis
The Germany Brugada Syndrome Market was valued at $43.9 Mn in 2023 and is predicted to grow at a CAGR of 6.0% from 2023 to 2030, to $66 Mn by 2030. The key drivers of the market include growing prevalence of cardiovascular diseases, increasing awareness and diagnosis, and advancements in genetic testing. The prominent players of the Germany Brugada Syndrome Market are Bayer, Roche, Siemens Healthineers, Sanofi, Thermo Fisher Scientific, and Novartis, among others.
Brazil Adult Malignant Glioma Therapeutics Market Analysis
The Brazil Adult Glioma Therapeutics Market is valued at around $55 Mn in 2022 and is projected to reach $117 Mn by 2030, exhibiting a CAGR of 9.9% during the forecast period. The market's growth is being driven by the advent of innovative targeted therapies as well as increased awareness, both of which are addressing the growing prevalence of glioma, which is aided by improved diagnostic instruments and early detection procedures. Key players in the Brazil Adult Malignant Glioma Therapeutics Market include companies like Roche, Merck & Co., Novartis, Pfizer, AbbVie, Oncoclínica, Cmed, EMS, DASA. Etc.
Philippines Brain Cancer Therapeutics Market
Philippines Brain Cancer Therapeutics Market valued at $5 Mn in 2022, projected to reach $12 Mn by 2030 with a 11.1% CAGR. Anticipated increases in the occurrence of brain cancer, particularly glioblastoma multiforme, are expected to substantially boost the need for treatments targeting brain cancer, thereby impacting the market's overall landscape. Currently, prominent pharmaceutical entities in the market include Merck & Co, Amgen, Roche, Pfizer, Teva Pharmaceutical, Karyopharm Therapeutics, Novartis, AstraZeneca, Bristol Myers Squibb, and Eli Lilly.